Stopping a Killer: 2020 Update on Reducing ASCVD Risk

Description

Cardiovascular disease remains the leading cause of morbidity and mortality in the United States, despite major improvements in atherosclerotic cardiovascular disease (ASCVD) risk management and prevention. Most Americans who had an ASCVD event reported at least one risk factor beforehand. So how do we move patients toward ideal cardiovascular health? 
Join the experts in this session discussing significant changes in the recent 2019 American College of Cardiology/American Heart Association (ACC/AHA) recommendations, including those for exercise, low-dose aspirin use, physical activities, tobacco use, and team-based care. 

This session is part of the Trending Topics in Ambulatory Care series and  provides a robust preparatory curriculum for the high-level pharmacy professional planning to take the BCACP examination or for those seeking BCACP recertification credit.

 

Pharmacist Learning Objectives

At the completion of this application-based activity, participants will be able to: 

  1. Discuss recent 2019 evidence-based updates from ACC/AHA on primary prevention of ASCVD.
  2. Identify the risk factors that increase ASCVD risk.
  3. Discuss the reasoning for the recent low-dose aspirin recommendation in the ACC/AHA guidelines. 
  4. Describe recommendations for appropriately selecting glycemic-lowering medications to reduce ASCVD risk in patients with type 2 diabetes.  
  5. Formulate patient-centered treatment plans for primary prevention patients with and without diabetes to reduce ASCVD. 

Technician Learning Objectives

At the completion of this application-based activity, participants will be able to: 

  1. Discuss recent 2019 evidence-based updates from ACC/AHA on primary prevention of ASCVD.
  2. Identify the risk factors that increase ASCVD risk.
  3. Discuss the reasoning for the recent low-dose aspirin recommendation in the ACC/AHA guidelines. 
  4. Describe recommendations for appropriately selecting glycemic-lowering medications to reduce ASCVD risk in patients with type 2 diabetes.  
  5. Formulate patient-centered treatment plans for primary prevention patients with and without diabetes to reduce ASCVD. 
 
 
 
Speakers:
Susan
Susan Cornell, PharmD, BS, FAPhA
Associate Professor
Midwestern University
 
Joseph
Joseph Saseen, PharmD, BCPS, BCACP
Professor and Vice Chair
University of Colorado
 
Learning Level: Level 3
Track: Ambulatory Care, Pharmacist Clinical Patient Care Services
Session Time Slot(s): 
Date: 
Sunday, March 22
Time: 
7:00 AM - 8:30 AM
Room: 
Gaylord National Resort - National Harbor 12-13
CEUs Pharmacist: 0.15
CEUs Pharmacy Technician: 0.15
Activity Type:
Application-based